Investigational drug · Phase 2
AFA-281
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alcohol Abuse, Alcohol Abuse/addiction, Anxiety.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "AFA-281"
First trial start
2025
Oct 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AFA-281", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alcohol Abuse
- Alcohol Abuse/addiction
- Anxiety
- Pain Threshold
- Depression Disorders
- Sleep Disorder
- Lumbosacral Radiculopathy
Approved drugs for the same conditions: Depression (major depressive disorder) · Anxiety disorders · Psychiatry · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "AFA-281" as an intervention, largest first.
- Safety and Efficacy Study on AFA-281 for the Treatment of Low Back PainPivotal-lookingNot yet recruiting
Afasci IncIndustry
NCT06649747 · 408 participants (planned) · Start Apr 1, 2027 · Primary completion Mar 31, 2032
Drug: AFA-281 · For: Lumbosacral Radiculopathy
- Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy VolunteersCompleted
Afasci IncIndustry
NCT05547503 · 64 participants · Start Apr 11, 2023 · Primary completion Dec 4, 2024
Drug: AFA-281 · For: Pain, Neuropathic; Pain, Inflammatory
Sites: Los Alamitos, California
- A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use DisorderNot yet recruiting
Afasci IncIndustry
NCT06710431 · 36 participants (planned) · Start Oct 1, 2025 · Primary completion Jun 1, 2027
Drug: AFA-281 · For: Alcohol Abuse; Alcohol Abuse/addiction; Anxiety and 3 more
Sites: Los Angeles, California
- A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy VolunteersNot yet recruiting
Afasci IncIndustry
NCT06719908 · 20 participants (planned) · Start Jul 1, 2025 · Primary completion Jul 1, 2026
Drug: AFA-281 is a small molecule, orally available · For: Alcohol; Alcohol Use Disorders
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.